Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5855686

NCc1ccccc1-n1cccn1.O=C(O)C(F)(F)F

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.45
TPH1 P17752 1/20 0.44
CACNA1G O43497 1/20 0.43
CACNA1H O95180 1/20 0.43
CACNA1I Q9P0X4 1/20 0.43
LMNA P02545 3/20 0.42
PDK1 Q15118 1/20 0.41
PDK2 Q15119 1/20 0.41
PDK3 Q15120 1/20 0.41
PDK4 Q16654 1/20 0.41
RORC P51449 1/20 0.40
NPC1 O15118 1/20 0.40
MAPK1 P28482 1/20 0.40
MPO P05164 3/20 0.38
DGAT1 O75907 2/20 0.38
F2 P00734 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL110394 0.85 NPC1 (0.51) ADORA2ATPH1CACNA1GCACNA1HCACNA1I
SCHEMBL10918669 0.77 NPC1 (0.46) ADORA2ATPH1CACNA1GCACNA1HCACNA1I
SCHEMBL11499234 0.76 TPH1 (0.45) ADORA2ATPH1CACNA1GCACNA1HCACNA1I
SCHEMBL5855691 0.75 ADORA2A (0.48) ADORA2ATPH1CACNA1GCACNA1HCACNA1I
SCHEMBL11493280 0.74 CACNA1G (0.47) ADORA2ATPH1CACNA1GCACNA1HCACNA1I
SCHEMBL12481069 0.74 MAPK1 (0.53) ADORA2ATPH1CACNA1GCACNA1HCACNA1I
SCHEMBL27632456 0.74 NPC1 (0.46) ADORA2ATPH1CACNA1GCACNA1HCACNA1I
SCHEMBL30332519 0.73 NPC1 (0.49) ADORA2ATPH1CACNA1GCACNA1HCACNA1I
SCHEMBL20773519 0.73 NPC1 (0.49) ADORA2ATPH1CACNA1GCACNA1HCACNA1I
SCHEMBL18584960 0.73 NPC1 (0.56) ADORA2ATPH1CACNA1GCACNA1HCACNA1I

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7144899-B2 Thrombin inhibitors MERCK & CO., INC. (US) 2006-12-05 US disclosed
US-7026324-B2 Thrombin inhibitors MERCK & CO., INC. (US) 2006-04-11 US disclosed
US-20040097730-A1 Thrombin inhibitors MERCK & CO., INC. 2004-05-20 US disclosed
US-20040073025-A1 Thrombin inhibitors MERCK SHARP & DOHME CORP. 2004-04-15 US disclosed
US-6610701-B2 For therapy and prophylaxis of blood coagulation and cardiovascular disorders MERCK & CO., INC. 2003-08-26 US disclosed
US-20020193398-A1 Thrombin inhibitors MERCK & CO., INC. 2002-12-19 US disclosed
WO-2002064559-A2 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097730-A1 Thrombin inhibitors F3, F2, SERPINC1 ADORA2A 3049/4885TPH1 3659/4885CACNA1G 1299/4885
US-20020193398-A1 Thrombin inhibitors F2, F3, TFPI ADORA2A 3421/4885TPH1 1108/4885CACNA1G 1260/4885
US-20040073025-A1 Thrombin inhibitors F2, F11, F10 ADORA2A 3432/4885TPH1 1622/4885CACNA1G 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.